HW-55 Chromatography Purifies Monomeric BSA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to isolate pure monomeric bovine serum albumin (BSA) from commercial preparations due to contamination with high molecular weight derivatives and saccharides, which hinders its use in research and therapeutic applications.
Innovation Solution
A method involving equilibration of a HW-55 column with a specific buffer, loading BSA, and eluting with the same buffer to obtain monomeric BSA, accompanied by charcoal treatment to remove hydrophobic ligands, and using dynamic light scattering for homogeneity confirmation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If Sephadex G-200 is used for molecular sieve fractionation to separate BSA monomer from high molecular weight aggregates, then separation of monomeric BSA is achieved, but saccharide contamination increases due to dextran molecules from the gel
Solution Approach 1:
The patent changes the pH parameter of the buffer system to 5.65, which is below the pI of BSA (4.7-5.0). This parameter change alters the charge state of BSA and its interaction with the HW-55S resin, enabling selective binding of monomeric BSA while excluding high molecular weight aggregates and reducing saccharide contamination compared to neutral pH Sephadex fractionation
Solution Approach 2:
The patent introduces n-butanol as an intermediary substance in the equilibration buffer (1% v/v). This intermediary modifies the hydrophobic interactions between BSA and the HW-55S resin, enhancing the selectivity for monomeric BSA and improving separation efficiency while minimizing saccharide co-elution
2Ease of manufacture
If commercial BSA preparations are used directly, then availability and cost-effectiveness are maintained, but high molecular weight derivatives and saccharide contaminants are present
Solution Approach 1:
The patent extracts and removes high molecular weight aggregates and saccharide contaminants from commercial BSA preparations through size-exclusion chromatography on HW-55S resin. The method selectively retains monomeric BSA in the eluate while excluding polymers and carbohydrate contaminants, thereby purifying the protein without requiring complete resynthesis
Solution Approach 2:
The patent performs preliminary fractionation of commercial BSA on HW-55S resin before use in sensitive applications. This preliminary purification step removes contaminants that would otherwise interfere with research experiments and therapeutic applications, enabling direct use of commercial preparations after simple processing
3Measurement precision
If SDS/PAGE is used for purity determination, then detection of high molecular weight forms is possible, but analysis time is lengthy
Solution Approach 1:
The patent replaces the mechanical separation process of SDS/PAGE with optical detection using dynamic light scattering (DLS). DLS measures the hydrodynamic radius of BSA molecules in solution, providing rapid differentiation between monomers and aggregates without requiring gel electrophoresis, thereby reducing analysis time from hours to minutes while maintaining detection capability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method yields highly homogeneous BSA with no saccharide contaminants, confirmed by dynamic light scattering, and reduces analysis time compared to conventional SDS/PAGE, ensuring the purity and suitability of BSA for research and therapeutic applications.
Implementation Method 1
The separation of the BSA monomer from such high molecular weight protein aggregates has been described, which makes use of fractionation in a column packed with the dextran gel Sephadex G-200
Implementation Method 2
Prior to using BSA in research, it is thus worthwhile to remove hydrophobic contaminants using charcoal
Implementation Method 3
The identification of the resulting BSA monomer via DLS is preferable due to the possibility of simultaneous determination of homogeneity (%) of the resulting albumin fractions
Data Source
Figure 1A~1C
Figure 2~4
Figure 3A~3B
AI summary
The subject of the present invention is a pure monomeric bovine serum albumin, a method of producing it characterised by the use column chromatography in resin and a method of identifying it using dynamic light scattering.